New Therapeutic Targets for Hepatic Fibrosis in the Integrin Family, α8β1 and α11β1, Induced Specifically on Activated Stellate Cells
Abstract
:1. Introduction
2. Leading Three Players in Fibrosis Are Each Related to Integrins
3. Activation of Latent TGFβ by Integrins
4. Trends of Target-Integrins for Fibrosis
5. What the History of αv-Integrin Inhibitors Tells Us
6. Disease Specific Integrins
7. Pathology Specific Integrin α8β1 with TGFβ-Activating Potential
7.1. Proposed Contribution of α8β1 to Fibrosis and Opposing Findings
7.2. Neutralizing mAb for α8β1
7.3. A Role of α8β1 in Fibrosis
8. Pathology Specific Integrin α11β1 with a Property of Collagen Receptor
9. Future Directions for Anti-Fibrotic Integrin Inhibitor Drugs
9.1. Evaluation in Animal Models
9.2. Target Specificity of Integrin Inhibitors and Pathology Specificity of Target Integrins
9.3. Combination Therapy
9.4. Allosteric Inhibition
10. Concluding Remarks
11. Patents
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Younossi, Z.M.; Koenig, A.B.; Abdelatif, D.; Fazel, Y.; Henry, L.; Wymer, M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016, 64, 73–84. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Estes, C.; Razavi, H.; Loomba, R.; Younossi, Z.; Sanyal, A.J. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 2018, 67, 123–133. [Google Scholar] [CrossRef]
- Marcellin, P.; Kutala, B.K. Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening. Liver Int. 2018, 38 (Suppl. S1), 2–6. [Google Scholar] [CrossRef] [Green Version]
- Chen, W.; Yang, A.; Jia, J.; Popov, Y.V.; Schuppan, D.; You, H. Lysyl Oxidase (LOX) Family Members: Rationale and Their Potential as Therapeutic Targets for Liver Fibrosis. Hepatology 2020, 72, 729–741. [Google Scholar] [CrossRef]
- Younossi, Z.M.; Stepanova, M.; Lawitz, E.; Charlton, M.; Loomba, R.; Myers, R.P.; Subramanian, M.; McHutchison, J.G.; Goodman, Z. Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib. Liver Int. 2018, 38, 1849–1859. [Google Scholar] [CrossRef] [PubMed]
- Slack, R.J.; Macdonald, S.J.F.; Roper, J.A.; Jenkins, R.G.; Hatley, R.J.D. Emerging therapeutic opportunities for integrin inhibitors. Nat. Rev. Drug Discov. 2021, 1–9. [Google Scholar] [CrossRef] [PubMed]
- Kim, K.K.; Sheppard, D.; Chapman, H.A. TGF-β1 Signaling and Tissue Fibrosis. Cold Spring Harb. Perspect. Biol. 2017, 10, a022293. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Reed, N.I.; Jo, H.; Chen, C.; Tsujino, K.; Arnold, T.D.; DeGrado, W.F.; Sheppard, D. The αvβ1 integrin plays a critical in vivo role in tissue fibrosis. Sci. Transl. Med. 2015, 7, 288ra279. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Horan, G.S.; Wood, S.; Ona, V.; Li, D.J.; Lukashev, M.E.; Weinreb, P.H.; Simon, K.J.; Hahm, K.; Allaire, N.E.; Rinaldi, N.J.; et al. Partial inhibition of integrin αvβ6 prevents pulmonary fibrosis without exacerbating inflammation. Am. J. Respir. Crit. Care Med. 2008, 177, 56–65. [Google Scholar] [CrossRef] [PubMed]
- Puthawala, K.; Hadjiangelis, N.; Jacoby, S.C.; Bayongan, E.; Zhao, Z.; Yang, Z.; Devitt, M.L.; Horan, G.S.; Weinreb, P.H.; Lukashev, M.E.; et al. Inhibition of integrin αvβ6, an activator of latent TGF-β, prevents radiation-induced lung fibrosis. Am. J. Respir. Crit. Care Med. 2008, 177, 82–90. [Google Scholar] [CrossRef]
- Nishimichi, N.; Tsujino, K.; Kanno, K.; Sentani, K.; Kobayashi, T.; Chayama, K.; Sheppard, D.; Yokosaki, Y. Induced hepatic stellate cell integrin, α8β1, enhances cellular contractility and TGFβ activity in liver fibrosis. J. Pathol. 2021, 253, 366–373. [Google Scholar] [CrossRef]
- Bansal, R.; Nakagawa, S.; Yazdani, S.; van Baarlen, J.; Venkatesh, A.; Koh, A.P.; Song, W.M.; Goossens, N.; Watanabe, H.; Beasley, M.B.; et al. Integrin α11 in the regulation of the myofibroblast phenotype: Implications for fibrotic diseases. Exp. Mol. Med. 2017, 49, e396. [Google Scholar] [CrossRef] [Green Version]
- Schwabe, R.F.; Tabas, I.; Pajvani, U.B. Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis. Gastroenterology 2020, 158, 1913–1928. [Google Scholar] [CrossRef] [PubMed]
- Schuppan, D.; Surabattula, R.; Wang, X.Y. Determinants of fibrosis progression and regression in NASH. J. Hepatol. 2018, 68, 238–250. [Google Scholar] [CrossRef]
- Lodyga, M.; Hinz, B. TGF-beta1—A truly transforming growth factor in fibrosis and immunity. Semin. Cell Dev. Biol. 2020, 101, 123–139. [Google Scholar] [CrossRef]
- Miranti, C.K.; Brugge, J.S. Sensing the environment: A historical perspective on integrin signal transduction. Nat. Cell. Biol. 2002, 4, 83–90. [Google Scholar] [CrossRef]
- Kechagia, J.Z.; Ivaska, J.; Roca-Cusachs, P. Integrins as biomechanical sensors of the microenvironment. Nat. Rev. Mol. Cell Biol. 2019, 20, 457–473. [Google Scholar] [CrossRef]
- Nolte, M.; Margadant, C. Controlling Immunity and Inflammation through Integrin-Dependent Regulation of TGF-β. Trends Cell Biol. 2020, 30, 49–59. [Google Scholar] [CrossRef] [PubMed]
- Hynes, R. Integrins: Versatility, Modulation, and Signaling in Cell Adhesion. Cell 1992, 69, 11–25. [Google Scholar] [CrossRef]
- Vestweber, D. How leukocytes cross the vascular endothelium. Nat. Rev. Immunol. 2015, 15, 692–704. [Google Scholar] [CrossRef]
- Reynolds, L.E.; Wyder, L.; Lively, J.C.; Taverna, D.; Robinson, S.D.; Huang, X.; Sheppard, D.; Hynes, R.O.; Hodivala-Dilke, K.M. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat. Med. 2002, 8, 27–34. [Google Scholar] [CrossRef]
- Lemos, D.R.; Duffield, J.S. Tissue-resident mesenchymal stromal cells: Implications for tissue-specific antifibrotic therapies. Sci. Transl. Med. 2018, 10, eaan5174. [Google Scholar] [CrossRef] [PubMed]
- Meng, X.M.; Nikolic-Paterson, D.J.; Lan, H.Y. TGF-β: The master regulator of fibrosis. Nat. Rev. Nephrol. 2016, 12, 325–338. [Google Scholar] [CrossRef]
- Munger, J.S.; Huang, X.; Kawakatsu, H.; Griffiths, M.J.D.; Dalton, S.L.; Wu, J.; Pittet, J.-F.; Kaminski, N.; Garat, C.; Matthay, M.A.; et al. The integrin αvβ6 binds and activates latent TGFβ1: A mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999, 96, 319–328. [Google Scholar] [CrossRef] [Green Version]
- Huang, X.Z.; Wu, J.F.; Cass, D.; Erle, D.J.; Corry, D.; Young, S.G.; Farese, R.V., Jr.; Sheppard, D. Inactivation of the integrin beta 6 subunit gene reveals a role of epithelial integrins in regulating inflammation in the lung and skin. J. Cell Biol. 1996, 133, 921–928. [Google Scholar] [CrossRef] [PubMed]
- Robertson, I.B.; Horiguchi, M.; Zilberberg, L.; Dabovic, B.; Hadjiolova, K.; Rifkin, D.B. Latent TGF-β-binding proteins. Matrix Biol. 2015, 47, 44–53. [Google Scholar] [CrossRef]
- Ruoslahti, E.; Pierschbacher, M.D. New perspectives in cell adhesion: RGD and integrins. Science 1987, 238, 491–497. [Google Scholar] [CrossRef] [PubMed]
- Pytela, R.; Pierschbacher, M.D.; Ruoslahti, E. Identification and isolation of a 140 kd cell surface glycoprotein with properties expected of a fibronectin receptor. Cell 1985, 40, 191–198. [Google Scholar] [CrossRef]
- Brooks, P.C.; Montgomery, A.M.; Rosenfeld, M.; Reisfeld, R.A.; Hu, T.; Klier, G.; Cheresh, D.A. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994, 79, 1157–1164. [Google Scholar] [CrossRef]
- Friedlander, M.; Brooks, P.C.; Shaffer, R.W.; Kincaid, C.M.; Varner, J.A.; Cheresh, D.A. Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995, 270, 1500–1502. [Google Scholar] [CrossRef]
- Sheppard, D. Endothelial integrins and angiogenesis: Not so simple anymore. J. Clin. Investig. 2002, 110, 913–914. [Google Scholar] [CrossRef]
- Decaris, M.L.; Schaub, J.R.; Chen, C.; Cha, J.; Lee, G.G.; Rexhepaj, M.; Ho, S.S.; Rao, V.; Marlow, M.M.; Kotak, P.; et al. Dual inhibition of αvβ6 and αvβ1 reduces fibrogenesis in lung tissue explants from patients with IPF. Respir. Res. 2021, 22, 265. [Google Scholar] [CrossRef]
- Wang, B.; Dolinski, B.M.; Kikuchi, N.; Leone, D.R.; Peters, M.G.; Weinreb, P.H.; Violette, S.M.; Bissell, D.M. Role of αvβ6 integrin in acute biliary fibrosis. Hepatology 2007, 46, 1404–1412. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ma, L.-J.; Yang, H.; Gaspert, A.; Carlesso, G.; Barty, M.M.; Davidson, J.M.; Sheppard, D.; Fogo, A.B. Transforming Growth Factor-β-Dependent and -Independent Pathways of Induction of Tubulointerstitial Fibrosis in β6−/− Mice. Am. J. Pathol. 2003, 163, 1261–1273. [Google Scholar] [CrossRef]
- Hahm, K.; Lukashev, M.E.; Luo, Y.; Yang, W.J.; Dolinski, B.M.; Weinreb, P.H.; Simon, K.J.; Chun Wang, L.; Leone, D.R.; Lobb, R.R.; et al. αvβ6 integrin regulates renal fibrosis and inflammation in Alport mouse. Am. J. Pathol. 2007, 170, 110–125. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Asano, Y.; Ihn, H.; Yamane, K.; Jinnin, M.; Mimura, Y.; Tamaki, K. Involvement of αvβ5 integrin-mediated activation of latent transforming growth factor beta1 in autocrine TGF-β signaling in systemic sclerosis fibroblasts. Arthritis Rheum. 2005, 52, 2897–2905. [Google Scholar] [CrossRef]
- Wipff, P.J.; Rifkin, D.B.; Meister, J.J.; Hinz, B. Myofibroblast contraction activates latent TGF-β1 from the extracellular matrix. J. Cell Biol. 2007, 179, 1311–1323. [Google Scholar] [CrossRef] [Green Version]
- Sarrazy, V.; Koehler, A.; Chow, M.L.; Zimina, E.; Li, C.X.; Kato, H.; Caldarone, C.A.; Hinz, B. Integrins αvβ5 and αvβ3 promote latent TGF-β1 activation by human cardiac fibroblast contraction. Cardiovasc. Res. 2014, 102, 407–417. [Google Scholar] [CrossRef] [Green Version]
- Henderson, N.C.; Arnold, T.D.; Katamura, Y.; Giacomini, M.M.; Rodriguez, J.D.; McCarty, J.H.; Pellicoro, A.; Raschperger, E.; Betsholtz, C.; Ruminski, P.G.; et al. Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat. Med. 2013, 19, 1617–1624. [Google Scholar] [CrossRef] [Green Version]
- Wilkinson, A.L.; Barrett, J.W.; Slack, R.J. Pharmacological characterisation of a tool αvβ1 integrin small molecule RGD-mimetic inhibitor. Eur. J. Pharmacol. 2019, 842, 239–247. [Google Scholar] [CrossRef]
- Coller, B.; Scudder, L.; Beer, J. Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents. Ann. N. Y. Acad. Sci. 1991, 614, 193–213. [Google Scholar] [CrossRef]
- Li, H.; Shi, F.-H.; Huang, S.-Y.; Zhang, S.-G.; Chen, M.-L. A Review on Clinical Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Natalizumab: A Humanized Anti-α4 Integrin Monoclonal Antibody. Curr. Drug Metab. 2018, 19, 1213–1223. [Google Scholar] [CrossRef]
- Rai, R.P.; Liu, Y.; Iyer, S.S.; Liu, S.; Gupta, B.; Desai, C.; Kumar, P.; Smith, T.; Singhi, A.D.; Nusrat, A.; et al. Blocking integrin α4β7-mediated CD4 T cell recruitment to the intestine and liver protects mice from western diet-induced non-alcoholic steatohepatitis. J. Hepatol. 2020, 73, 1013–1022. [Google Scholar] [CrossRef]
- Gerard, A.; Cope, A.P.; Kemper, C.; Alon, R.; Kochl, R. LFA-1 in T cell priming, differentiation, and effector functions. Trends Immunol. 2021, 42, 706–722. [Google Scholar] [CrossRef]
- Perez, V.L.; Pflugfelder, S.C.; Zhang, S.; Shojaei, A.; Haque, R. Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease. Ocul. Surf. 2016, 14, 207–215. [Google Scholar] [CrossRef] [Green Version]
- Ulmasov, B.; Neuschwander-Tetri, B.A.; Lai, J.; Monastyrskiy, V.; Bhat, T.; Yates, M.P.; Oliva, J.; Prinsen, M.J.; Ruminski, P.G.; Griggs, D.W. Inhibitors of Arg-Gly-Asp-Binding Integrins Reduce Development of Pancreatic Fibrosis in Mice. Cell. Mol. Gastroenterol. Hepatol. 2016, 2, 499–518. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ulmasov, B.; Noritake, H.; Carmichael, P.; Oshima, K.; Griggs, D.W.; Neuschwander-Tetri, B.A. An Inhibitor of Arginine-Glycine-Aspartate-Binding Integrins Reverses Fibrosis in a Mouse Model of Nonalcoholic Steatohepatitis. Hepatol. Commun. 2019, 3, 246–261. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kossen, K.; Schaefer, C.; Lim, S.; Michener, M.; Ruminiski, P.; Griggs, D.; Radhakrishnan, R.; Bradford, B.; Seiwert, S. IDL-2965: A Selective, highly-potent, oral Integrin antagonist for IPF. Eur. Respir. J. 2019, 54, PA5374. [Google Scholar]
- Chew, D.P.; Bhatt, D.L.; Sapp, S.; Topol, E.J. Increased Mortality With Oral Platelet Glycoprotein IIb/IIIa Antagonists. A Meta-Analysis of Phase III Multicenter Randomized Trials. Circulation 2001, 103, 201–206. [Google Scholar] [CrossRef] [PubMed]
- Cox, D.; Brennan, M.; Moran, N. Integrins as therapeutic targets: Lessons and opportunities. Nat. Rev. Drug. Discov. 2010, 9, 804–820. [Google Scholar] [CrossRef]
- Van Agthoven, J.F.; Xiong, J.P.; Alonso, J.L.; Rui, X.; Adair, B.D.; Goodman, S.L.; Arnaout, M.A. Structural basis for pure antagonism of integrin αVβ3 by a high-affinity form of fibronectin. Nat. Struct. Mol. Biol. 2014, 21, 383–388. [Google Scholar] [CrossRef] [Green Version]
- Dong, X.; Hudson, N.E.; Lu, C.; Springer, T.A. Structural determinants of integrin beta-subunit specificity for latent TGF-beta. Nat. Struct. Mol. Biol. 2014, 21, 1091–1096. [Google Scholar] [CrossRef] [Green Version]
- Dong, X.; Zhao, B.; Lin, F.Y.; Lu, C.; Rogers, B.N.; Springer, T.A. High integrin αVβ6 affinity reached by hybrid domain deletion slows ligand-binding on-rate. Proc. Natl. Acad. Sci. USA 2018, 115, E1429–E1436. [Google Scholar] [CrossRef] [Green Version]
- Dong, X.; Zhao, B.; Iacob, R.E.; Zhu, J.; Koksal, A.C.; Lu, C.; Engen, J.R.; Springer, T.A. Force interacts with macromolecular structure in activation of TGF-β. Nature 2017, 542, 55–59. [Google Scholar] [CrossRef] [PubMed]
- Hatley, R.J.D.; Macdonald, S.J.F.; Slack, R.J.; Le, J.; Ludbrook, S.B.; Lukey, P.T. An αv-RGD integrin inhibitor toolbox: Drug discovery insight, challenges and opportunities. Angew. Chem. Int. Ed. Engl. 2018, 57, 3298–3321. [Google Scholar] [CrossRef]
- John, A.E.; Graves, R.H.; Pun, K.T.; Vitulli, G.; Forty, E.J.; Mercer, P.F.; Morrell, J.L.; Barrett, J.W.; Rogers, R.F.; Hafeji, M.; et al. Translational pharmacology of an inhaled small molecule alphavbeta6 integrin inhibitor for idiopathic pulmonary fibrosis. Nat. Commun. 2020, 11, 4659. [Google Scholar] [CrossRef]
- Sundaram, A.; Chen, C.; Isik Reed, N.; Liu, S.; Ki Yeon, S.; McIntosh, J.; Tang, Y.Z.; Yang, H.; Adler, M.; Beresis, R.; et al. Dual antagonists of α5β1/αvβ1 integrin for airway hyperresponsiveness. Bioorg. Med. Chem. Lett. 2020, 30, 127578. [Google Scholar] [CrossRef]
- Han, Z.; Ma, Y.; Cao, G.; Ma, Z.; Chen, R.; Cvijic, M.E.; Cheng, D. Integrin αVβ1 regulates procollagen I production through a non-canonical transforming growth factor β signaling pathway in human hepatic stellate cells. Biochem. J. 2021, 478, 1689–1703. [Google Scholar] [CrossRef] [PubMed]
- Hatley, R.J.D.; Barrett, T.N.; Slack, R.J.; Watson, M.E.; Baillache, D.J.; Gruszka, A.; Washio, Y.; Rowedder, J.E.; Pogány, P.; Pal, S.; et al. The Design of Potent, Selective and Drug-Like RGD αvβ1 Small-Molecule Inhibitors Derived from non-RGD α4β1 Antagonists. ChemMedChem 2019, 14, 1315–1320. [Google Scholar] [CrossRef] [PubMed]
- Sheppard, D.; Cohen, D.S.; Wang, A.; Busk, M. TGFβ differentially regulates expression of integrin subunits in guinea pig airway epithelial cells. J. Biol. Chem. 1992, 267, 17409–17414. [Google Scholar] [CrossRef]
- Schnapp, L.M.; Breuss, J.M.; Ramos, D.M.; Sheppard, D.; Pytela, R. Sequence and tissue distribution of the human integrin α8 subunit: A β1-associated α subunit expressed in smooth muscle cells. J. Cell Sci. 1995, 108, 537–544. [Google Scholar] [CrossRef] [PubMed]
- Ono, H.; Ogasawara, O.; Okubo, K.; Bono, H. RefEx, a reference gene expression dataset as a web tool for the functional analysis of genes. Sci. Data 2017, 4, 170105. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Martin, K.; Pritchett, J.; Llewellyn, J.; Mullan, A.F.; Athwal, V.S.; Dobie, R.; Harvey, E.; Zeef, L.; Farrow, S.; Streuli, C.; et al. PAK proteins and YAP-1 signalling downstream of integrin β1 in myofibroblasts promote liver fibrosis. Nat. Commun. 2016, 7, 12502. [Google Scholar] [CrossRef]
- Levine, D.; Rockey, D.C.; Milner, T.A.; Breuss, J.M.; Fallon, J.T.; Schnapp, L.M. Expression of the Integrin α8β1 during pulmonary and hepatic fibrosis. Am. J. Pathol. 2000, 156, 1927–1935. [Google Scholar] [CrossRef]
- Thibault, G.; Lacombe, M.-J.; Schnapp, L.M.; Lacasse, A.; Bouzeghrane, F.; Lapalme, G.V. Upregulation of α8β1-integrin in cardiac fibroblast by angiotensin II and transforming growth factor- 1. Am. J. Physiol. Cell Physiol. 2001, 281, C1457–C1467. [Google Scholar] [CrossRef]
- Zargham, R.; Pepin, J.; Thibault, G. α8β1 Integrin is up-regulated in the neointima concomitant with late luminal loss after balloon injury. Cardiovasc. Pathol. 2007, 16, 212–220. [Google Scholar] [CrossRef]
- Ju, Y.; Huang, L.; Wang, S.; Zhao, S. Transcriptional Analysis Reveals Key Genes in the Pathogenesis of Nifedipine-Induced Gingival Overgrowth. Anal. Cell. Pathol. 2020, 2020, 6128341. [Google Scholar] [CrossRef]
- Lu, M.; Munger, J.S.; Steadele, M.; Busald, C.; Tellier, M.; Schnapp, L.M. Integrin α8β1 mediates adhesion to LAP-TGFβ1. J. Cell Sci. 2002, 115, 4641–4648. [Google Scholar] [CrossRef] [Green Version]
- Hartner, A.; Cordasic, N.; Rascher, W.; Hilgers, K.F. Deletion of the α8 integrin gene does not protect mice from myocardial fibrosis in DOCA hypertension. Am. J. Hypertens. 2009, 22, 92–99. [Google Scholar] [CrossRef] [Green Version]
- Hartner, A.; Menendez-Castro, C.; Cordasic, N.; Marek, I.; Volkert, G.; Klanke, B.; Rascher, W.; Hilgers, K.F. Tubulointerstitial de novo expression of the α8 integrin chain in a rodent model of renal fibrosis—A potential target for anti-fibrotic therapy? PLoS ONE 2012, 7, e48362. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Muller, U.; Wang, D.; Denda, S.; Meneses, J.J.; Pedersen, R.A.; Reichardt, L.F. Integrin α8β1 Is Critically Important for Epithelial–Mesenchymal Interactions during Kidney Morphogenesis. Cell 1997, 88, 603–613. [Google Scholar] [CrossRef] [Green Version]
- Humbert, C.; Silbermann, F.; Morar, B.; Parisot, M.; Zarhrate, M.; Masson, C.; Tores, F.; Blanchet, P.; Perez, M.J.; Petrov, Y.; et al. Integrin α8 recessive mutations are responsible for bilateral renal agenesis in humans. Am. J. Hum. Genet. 2014, 94, 288–294. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rossi, A.; Kontarakis, Z.; Gerri, C.; Nolte, H.; Holper, S.; Kruger, M.; Stainier, D.Y. Genetic compensation induced by deleterious mutations but not gene knockdowns. Nature 2015, 524, 230–233. [Google Scholar] [CrossRef]
- Hartner, A.; Cordasic, N.; Klanke, B.; Müller, U.M.; Sterzel, R.B.; Hilgers, K.F. The α8 integrin chain affords mechanical stability to the glomerular capillary tuft in hypertensive glomerular disease. Am. J. Pathol. 2002, 160, 861–867. [Google Scholar] [CrossRef]
- Byron, A.; Humphries, J.D.; Askari, J.A.; Craig, S.E.; Mould, A.P.; Humphries, M.J. Anti-integrin monoclonal antibodies. J. Cell Sci. 2009, 122, 4009–4011. [Google Scholar] [CrossRef] [Green Version]
- Nishimichi, N.; Kawashima, N.; Yokosaki, Y. Epitopes in α8β1 and other RGD-binding integrins delineate classes of integrin-blocking antibodies and major binding loops in α subunits. Sci. Rep. 2015, 5, 13756. [Google Scholar] [CrossRef] [Green Version]
- Fujiwara, H.; Ferreira, M.; Donati, G.; Marciano, D.; Linton, J.; Sato, Y.; Hartner, A.; Sekiguchi, K.; Reichardt, L.; Watt, F. The basement membrane of hair follicle stem cells is a muscle cell niche. Cell 2011, 144, 577–589. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Evans, A.L.; Müller, U. Stereocilia defects in the sensory hair cells of the inner ear in mice deficient in integrin α8β1. Nat. Gene 2000, 24, 424–428. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Linton, J.M.; Martin, G.R.; Reichardt, L.F. The ECM protein nephronectin promotes kidney development via integrin α8β1-mediated stimulation of Gdnf expression. Development 2007, 134, 2501–2509. [Google Scholar] [CrossRef] [Green Version]
- Cai, Q.; Chen, F.; Xu, F.; Wang, K.; Zhang, K.; Li, G.; Chen, J.; Deng, H.; He, Q. Epigenetic silencing of microRNA-125b-5p promotes liver fibrosis in nonalcoholic fatty liver disease via integrin α8-mediated activation of RhoA signaling pathway. Metabolism 2020, 2020, 154140. [Google Scholar] [CrossRef]
- Yang, A.; Yan, X.; Xu, H.; Fan, X.; Zhang, M.; Huang, T.; Li, W.; Chen, W.; Jia, J.; You, H. Selective depletion of hepatic stellate cells-specific LOXL1 alleviates liver fibrosis. FASEB J. 2021, 35, e21918. [Google Scholar] [CrossRef]
- Musiime, M.; Chang, J.; Hansen, U.; Kadler, K.E.; Zeltz, C.; Gullberg, D. Collagen Assembly at the Cell Surface: Dogmas Revisited. Cells 2021, 10, 662. [Google Scholar] [CrossRef]
- Zeltz, C.; Gullberg, D. The integrin-collagen connection—A glue for tissue repair? J. Cell Sci. 2016, 129, 1284. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Popova, S.N.; Rodriguez-Sanchez, B.; Liden, A.; Betsholtz, C.; Van Den Bos, T.; Gullberg, D. The mesenchymal α11β1 integrin attenuates PDGF-BB-stimulated chemotaxis of embryonic fibroblasts on collagens. Dev. Biol. 2004, 270, 427–442. [Google Scholar] [CrossRef] [PubMed]
- Zeltz, C.; Lu, N.; Gullberg, D. Integrin α11β1: A major collagen receptor on fibroblastic cells. In I-Domain Integrins; Advances in Experimental Medicine and Biology; Springer: London, UK, 2014; pp. 73–84. [Google Scholar]
- Talior-Volodarsky, I.; Connelly, K.A.; Arora, P.D.; Gullberg, D.; McCulloch, C.A. α11 Ιntegrin stimulates myofibroblast differentiation in diabetic cardiomyopathy. Cardiovasc. Res. 2012, 96, 265–275. [Google Scholar] [CrossRef] [Green Version]
- Civitarese, R.A.; Talior-Volodarsky, I.; Desjardins, J.F.; Kabir, G.; Switzer, J.; Mitchell, M.; Kapus, A.; McCulloch, C.A.; Gullberg, D.; Connelly, K.A. The α11 integrin mediates fibroblast-extracellular matrix-cardiomyocyte interactions in health and disease. Am. J. Physiol. Heart Circ. Physiol. 2016, 311, H96–H106. [Google Scholar] [CrossRef] [PubMed]
- Carracedo, S.; Lu, N.; Popova, S.N.; Jonsson, R.; Eckes, B.; Gullberg, D. The fibroblast integrin α11β1 is induced in a mechanosensitive manner involving activin A and regulates myofibroblast differentiation. J. Biol. Chem. 2010, 285, 10434–10445. [Google Scholar] [CrossRef] [Green Version]
- Lu, N.; Carracedo, S.; Ranta, J.; Heuchel, R.; Soininen, R.; Gullberg, D. The human α11 integrin promoter drives fibroblast-restricted expression in vivo and is regulated by TGF-β1 in a Smad- and Sp1-dependent manner. Matrix Biol. 2010, 29, 166–176. [Google Scholar] [CrossRef] [PubMed]
- Romaine, A.; Sorensen, I.W.; Zeltz, C.; Lu, N.; Erusappan, P.M.; Melleby, A.O.; Zhang, L.; Bendiksen, B.; Robinson, E.L.; Aronsen, J.M.; et al. Overexpression of integrin α11 induces cardiac fibrosis in mice. Acta Physiol. 2018, 222, e12932. [Google Scholar] [CrossRef] [PubMed]
- Mould, A.P.; Craig, S.E.; Byron, S.K.; Humphries, M.J.; Jowitt, T.A. Disruption of integrin-fibronectin complexes by allosteric but not ligand-mimetic inhibitors. Biochem. J. 2014, 464, 301–313. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mould, A.P.; Askari, J.A.; Byron, A.; Takada, Y.; Jowitt, T.A.; Humphries, M.J. Ligand-induced epitope masking. Dissociation of integrin α5β1-fibronectin complexes only by monoclonal antibodies with an allosteric mode of action. J. Biol. Chem. 2016, 291, 20993–21007. [Google Scholar] [CrossRef] [Green Version]
- Pihlajaniemi, T.; Myllyla, R.; Kivirikko, K. Prolyl 4-hydrox- ylase and its role in collagen synthesis. J. Hepatol. 1991, 13, S2–S7. [Google Scholar] [CrossRef]
- Friedman, S.L.; Neuschwander-Tetri, B.A.; Rinella, M.; Sanyal, A.J. Mechanisms of NAFLD development and therapeutic strategies. Nat. Med. 2018, 24, 908–922. [Google Scholar] [CrossRef] [PubMed]
- Tamayo, R.P. Is Cirrhosis of the Liver Experimentally Produced by CCl4 an Adequate Model of Human Cirrhosis? Hepatology 1983, 3, 112–120. [Google Scholar] [CrossRef] [PubMed]
- Buitrago, L.; Zafar, H.; Zhang, Y.; Li, J.; Walz, T.; Coller, B.S. Dominant role of αIIbβ3 in platelet interactions with cross-linked fibrin fragment D-dimer. Blood Adv. 2020, 4, 2939–2949. [Google Scholar] [CrossRef]
- Sehr, T.; Proschmann, U.; Thomas, K.; Marggraf, M.; Straube, E.; Reichmann, H.; Chan, A.; Ziemssen, T. New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies. J. Neuroinflamm. 2016, 13, 164. [Google Scholar] [CrossRef] [Green Version]
- Boziki, M.; Bakirtzis, C.; Giantzi, V.; Sintila, S.A.; Kallivoulos, S.; Afrantou, T.; Nikolaidis, I.; Ioannidis, P.; Karapanayiotides, T.; Koutroulou, I.; et al. Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center. Front. Neurol. 2021, 12, 699844. [Google Scholar] [CrossRef]
- Singh, S.; Murad, M.H.; Fumery, M.; Sedano, R.; Jairath, V.; Panaccione, R.; JSandborn, W.; Ma, C. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn’s disease: A systematic review and network meta-analysis. Lancet Gastroenterol. Hepatol. 2021, 6, 1002–1014. [Google Scholar] [CrossRef]
- Holland, E.J.; Jackson, M.A.; Donnenfeld, E.; Piccolo, R.; Cohen, A.; Barabino, S.; Rolando, M.; Figueiredo, F.C. Efficacy of Lifitegrast Ophthalmic Solution, 5.0%, in Patients With Moderate to Severe Dry Eye Disease: A Post Hoc Analysis of 2 Randomized Clinical Trials. JAMA Ophthalmol. 2021, 139, 1200–1208. [Google Scholar] [CrossRef] [PubMed]
- Yu, Y.; Schurpf, T.; Springer, T.A. How natalizumab binds and antagonizes α4 integrins. J. Biol. Chem. 2013, 288, 32314–32325. [Google Scholar] [CrossRef] [Green Version]
- Bouvet, M.; Claude, O.; Roux, M.; Skelly, D.; Masurkar, N.; Mougenot, N.; Nadaud, S.; Blanc, C.; Delacroix, C.; Chardonnet, S.; et al. Anti-integrin α(v) therapy improves cardiac fibrosis after myocardial infarction by blunting cardiac PW1(+) stromal cells. Sci. Rep. 2020, 10, 11404. [Google Scholar] [CrossRef] [PubMed]
- Alcaraz, L.B.; Exposito, J.Y.; Chuvin, N.; Pommier, R.M.; Cluzel, C.; Martel, S.; Sentis, S.; Bartholin, L.; Lethias, C.; Valcourt, U. Tenascin-X promotes epithelial-to-mesenchymal transition by activating latent TGF-β. J. Cell Biol. 2014, 205, 409–428. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Yokosaki, Y.; Nishimichi, N. New Therapeutic Targets for Hepatic Fibrosis in the Integrin Family, α8β1 and α11β1, Induced Specifically on Activated Stellate Cells. Int. J. Mol. Sci. 2021, 22, 12794. https://doi.org/10.3390/ijms222312794
Yokosaki Y, Nishimichi N. New Therapeutic Targets for Hepatic Fibrosis in the Integrin Family, α8β1 and α11β1, Induced Specifically on Activated Stellate Cells. International Journal of Molecular Sciences. 2021; 22(23):12794. https://doi.org/10.3390/ijms222312794
Chicago/Turabian StyleYokosaki, Yasuyuki, and Norihisa Nishimichi. 2021. "New Therapeutic Targets for Hepatic Fibrosis in the Integrin Family, α8β1 and α11β1, Induced Specifically on Activated Stellate Cells" International Journal of Molecular Sciences 22, no. 23: 12794. https://doi.org/10.3390/ijms222312794